Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2011

View Archived Issues

Curacyte terminates phase III study of PHP

Results from RUBY-1 trial investigating darexaban in acute coronary syndrome reported

Phase I/II trial assesses everolimus in tuberous sclerosis complex

Preclinical data presented on dual orexin OX1/OX2 receptor antagonist developed at Merck & Co.

Gilead discloses results from evaluation of HCV NS3/NS4A inhibitor in healthy volunteers

Randomized phase II trial evaluates alfuzosin in women with voiding dysfunction

Bayer Schering Pharma discloses novel progesterone receptor antagonists

Bristol-Myers Squibb divulges new serine protease inhibitors

New acetyl-CoA carboxylase inhibitors claimed by Bayer Schering Pharma

Scientists at Ironwood Pharmaceuticals present novel agents for pain

Duloxetine blocks psychostimulant effects

New glucocorticoid receptor ligands synthesized

Shire reflects on first half of 2011

PTC Therapeutics and Genzyme restructure collaboration agreement for ataluren

SuperGen to become Astex Pharmaceuticals

Avantra Biosciences changes name to Courtagen Life Sciences

Royal DSM and Sinochem establish global joint venture

Gilead to amend clinical trials of GS-9190 in HCV infection

SkyePharma completes proof-of-concept study of SKP-1052

European Commission approves Afinitor for new indication

Trastuzumab enters phase II trial in Paget's disease

Marketing authorization filed for tesamorelin in Argentina

OXiGENE restructures clinical programs for Zybrestat and OXI-4503

Addex Pharmaceuticals regains rights to metabotropic glutamate mGlu4 receptor PAM program

Mesoblast clear to initiate phase II trial of Revascor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...